Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

Active
PAR-28-063Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is offering the Research Specialist Award (R50) under solicitation PAR-28-063 to support exceptional clinician scientists involved in NCI-funded clinical trials research. This award aims to create stable career paths for professionals who provide leadership in developing national clinical trials, implementing these trials within their own institutions, and serving on scientific review or monitoring committees. The program is specifically designed for those who wish to maintain a high level of influence and service within NCI clinical trials networks without serving as principal investigators on research project grants. By providing dedicated salary support and increased professional autonomy, the award ensures that these vital clinician scientists are not solely dependent on external funding or grants held by other individuals. This initiative is intended to sustain the overall NCI clinical trials enterprise by securing the continuity of experienced research careers. Applications for this federal opportunity are open until February 21, 2029.

General Info

NCI R50 award provides salary support for clinician scientists in clinical trials research.

Agency

National Institutes Of Health → National Cancer Institute

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Cancer Institute
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Cancer Institute
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
International
RFI Tactical Cache System
Solicitation # MEGRFI/01013
The Ministry of Defence, specifically the Royal Navy, has issued a Request for Information (RFI) under solicitation number MEGRFI/01013 to identify suppliers capable of research, development, and experimentation (RD&E) for a modular Tactical Cache System. The objective is to develop a scalable system for the protected storage, handling, and management of authorized equipment and commodities within austere operating environments. Key capability areas of interest for the FY26/27 period include modular cache solutions, safe transport and recovery arrangements, environmental protection against water and condensation, configurable visual and thermal signature management, and secure, low-power status monitoring. This RFI is not a formal tender competition or a commitment to future contracts, and responses will be used for information purposes only to assist in the development of future requirements. Interested parties must submit their responses using the Annex A questionnaire via email to [email hidden] by 12:00 on November 20, 2026. All submissions must be classified as OFFICIAL, and any proprietary information must be clearly marked. Respondents are required to provide details on their SME status, prior experience with the Ministry of Defence, and their familiarity with Social Value objectives.
Ministry of Defence

POSTED

about 9 hours ago

DEADLINE

in 15 days
View Details
NAICS: 541715
New
Federal
Data Science & ML Algorithm DevelopmentThis subcontract, titled Data Science and ML Algorithm Development, focuses on the research and development of emerging data analytic techniques and machine learning models. Supporting prime contractors on FHWA Exploratory Advanced Research projects, the work involves creating predictive models and analytic techniques centered on highway safety, durability, and productivity. The primary objective is to advance technology from Technology Readiness Level 3 toward Level 7. Managed by the Department of Transportation under the 693JJ3 Acquisition and Grants Mgt agency, the contract requires the delivery of validated algorithms, technical reports, research papers, and analytic demonstrations. The opportunity is categorized under NAICS code 541715, with a response deadline set for December 21, 2026.
693JJ3 Acquisition And Grants Mgt

POSTED

about 12 hours ago

DEADLINE

in about 2 months
View Details
NAICS: 541715
New
Federal
Clinical Research Site Coordination and RecruitmentThis subcontract for Clinical Research Site Coordination and Recruitment supports prime contractors on NIH/NIMHD research projects. The scope of work focuses on the execution of clinical trials, specifically managing the recruitment and retention of diverse patient populations in real-world settings. Key responsibilities include patient enrollment, the collection of biospecimens, and the utilization of cold chain storage and Clinical Trial Management Systems to ensure data integrity. The project requires strict adherence to FDA, GCP, and IRB compliance standards to deliver qualified study cohorts and accurate patient data. Performance will take place in Bethesda, under the oversight of the National Institutes of Health. Interested parties should note the response deadline of November 19, 2026.
National Institutes Of Health Nichd

POSTED

about 12 hours ago

DEADLINE

in 15 days
View Details
NAICS: 541715
New
Federal
Bioinformatics Algorithm Development & IntegrationThis subcontract for Bioinformatics Algorithm Development and Integration supports prime contractors on USPTO biosequence tool projects under the Department of Commerce. The primary objective is the development and implementation of a functional biosequence alignment engine capable of high-accuracy one-to-one nucleotide and protein alignment searching. The scope of work involves creating alignment algorithms and optimizing their performance against large-scale biological databases. This technical execution requires the use of high-performance computing environments and established libraries such as BLAST or Smith-Waterman. The project is based in Alexandria, Virginia, with a response deadline of November 17, 2026.
Department Of Commerce Pto

POSTED

about 12 hours ago

DEADLINE

in 13 days
View Details
NAICS: 541715
New
Federal
Meteorological & Computational Chemistry Modeling
FA7022 Amic Det 2 Ol Patrick Pka

POSTED

about 12 hours ago

DEADLINE

in over 2 years
View Details
NAICS: 541715
New
Federal
Atmospheric and Space Signal Analysis
FA7022 Amic Det 2 Ol Patrick Pka

POSTED

about 12 hours ago

DEADLINE

in over 2 years
View Details
NAICS: 541715
New
Federal
Geophysics and Seismology Research
FA7022 Amic Det 2 Ol Patrick Pka

POSTED

about 12 hours ago

DEADLINE

in over 2 years
View Details
NAICS: 541715
New
Federal
AI/ML & NLP Data AnalysisThis subcontract opportunity, titled AI/ML & NLP Data Analysis, is issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services. The project focuses on providing AI-augmented scientific and regulatory analysis to support prime contractors on FDA regulatory projects. The selected provider will utilize Machine Learning and Natural Language Processing to extract critical insights from regulatory submissions and assist in the scientific review process, delivering data-driven analytical reports. The contract is designated as a Total Small Business Set Aside under NAICS code 541715, with the place of performance located in Silver Spring. Interested parties must possess specialized expertise in AI/ML frameworks and NLP specifically tailored for medical and regulatory text. The solicitation was posted on November 4, 2026, with a response deadline of November 19, 2026.
FDA Office Of Acq Grant Svcs

POSTED

about 12 hours ago

DEADLINE

in 15 days
View Details
NAICS: 541715
New
Federal
EmbraceHEALTH Clinical Research Network (EmbraceHEALTH CRN)
Solicitation # 75N94027R00002
The National Institute on Minority Health and Health Disparities (NIMHD) within the National Institutes of Health (NIH) has issued a Small Business Sources Sought Notice (75N94027R00002) to identify qualified small businesses capable of establishing and operating Research Consortia within the EmbraceHEALTH Clinical Research Network. The primary objective is to conduct solutions-oriented clinical, behavioral, and health services research aimed at reducing health disparities and improving health outcomes for affected populations across the U.S. and its territories. The anticipated contract vehicle is an Indefinite Delivery, Indefinite Quantity (IDIQ) agreement with an approximate five-year ordering period, where specific research activities will be assigned on a task order basis. Qualified respondents must operate under NAICS code 541715, with a small business size standard of 1,000 employees or less. To be deemed capable, organizations must demonstrate extensive experience in managing clinical and behavioral intervention studies in real-world healthcare settings, specifically those involving populations experiencing health disparities. Required capabilities include expertise in biostatistics, implementation science, data science, and informatics, as well as the infrastructure for electronic health record extraction, biospecimen collection, and secure data management. All clinical trials must adhere to FDA regulations and Good Clinical Practice (GCP) requirements. Interested small businesses, including SDB, WOSB, HUBZone, VOSB, and SDVOSB designations, must submit a capability statement by November 19, 2026. This statement must include the company's UEI, physical address, point of contact information, and details regarding any teaming arrangements or commercial availability of services. Submissions should be sent in MS Word or PDF format to Contract Specialist Jordan Neal and Contracting Officer Gannon White. This notice is for market research purposes only and does not constitute a formal solicitation or an obligation for the government to award a contract.
National Institutes Of Health Nichd

POSTED

about 12 hours ago

DEADLINE

in 15 days
View Details
NAICS: 541715
New
Federal
Mission System R and D Support for Blossom Point Tracking Facility (BPTF)
Solicitation # N0017327R0002
Naval Research Laboratory

POSTED

about 12 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541715
New
Federal
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
Solicitation # HT9427-26-R-E020
The Defense Health Agency Contracting Activity is seeking a single award to develop a Battlefield Wound Infection Prevention and Treatment Barrier Combination prototype. This medical product must integrate a physical wound barrier with antimicrobial and antifungal properties to prevent the spread of organisms and systemic infections in combat scenarios. The project aims to advance technologies starting at Technology Readiness Level 5 or higher, with the ultimate goal of achieving TRL 7 or 8. Key requirements include the execution of preclinical testing and human clinical trials, the development of Chemistry, Manufacturing, and Controls documentation, and the successful submission for FDA approval or clearance. The procurement is conducted under prototype Other Transaction Authority 10 U.S.C. 4022, meaning it utilizes a tailored agreement rather than standard FAR-based contract structures. The estimated period of performance is 48 months, divided into three primary objectives: prototype demonstration, clinical studies and regulatory submissions, and final FDA clearance. The final deliverable includes up to 50 final design prototypes for operational testing. Packaging must be individual, waterproof, and capable of being opened with gloved hands in low-light environments, while maintaining sterilization and resisting temperatures between 0 and 110 degrees Fahrenheit. Proposals are evaluated based on technical capability, management capability, and cost. Eligible participants are typically small businesses or nontraditional defense contractors; otherwise, a one-third non-federal cost share is required. Awardees must maintain active SAM registration and comply with CMMC cybersecurity frameworks and DoD instructions for Controlled Unclassified Information. Payments are processed electronically via Wide Area Workflow within 30 days of an acceptable invoice.
Defense Health Agency

POSTED

about 12 hours ago

DEADLINE

in 16 days
View Details
NAICS: 541715
New
Federal
Support design and structural analysis for Hiwrap, MBARS, CRS and COSSIR instruments on the NASA WB57 aircraft
Solicitation # 80NSSC27947412Q
The NASA Shared Services Center is seeking support for the design and structural analysis of mechanical interfaces for microwave instruments to be flown on a 6-foot pallet within the NASA WB-57 aircraft. The scope of work specifically covers the High-Altitude Wind and Rain Airborne Profiler (HIWRAP), Microwave Barometric Radar and Sounder (MBARS) or Cloud Radar System (CRS), and the Configurable Scanning Submillimeter-wave Instrument/Radiometer (COSSIR). Key deliverables include the design of a 18.5-inch diameter Gaussian optics lens antenna in a nadir configuration, a second Ku-band antenna with a 12-inch aperture and aluminum flat splash-plate reflector, and structural mounting plates for electronics boxes. All designs and mechanical analyses must adhere to the WB-57 Experimenter’s Handbook AOD 33890 Rev C PCN 2, with specific technical requirements for mirror flatness better than 150 microns and surface roughness no more than 50 microns. NASA intends to issue a sole source contract to Welch Mechanical Designs, LLC under the authority of FAR 12.102(a), as they have been determined to be the sole provider for these services. The procurement is categorized under NAICS code 541715 and will be conducted as a commercial acquisition per FAR Part 12. While the NASA Shared Services Center is the procuring center, performance will be located at the NASA Goddard Space Flight Center. The period of performance extends from the date of task award through April 1, 2027. Interested organizations may submit capability statements by November 9, 2026, to determine if the procurement will be conducted on a competitive basis; however, formal quotes will not be evaluated at this stage.
NASA Shared Services Center

POSTED

about 12 hours ago

DEADLINE

in 5 days
View Details

More opportunities from National Institutes Of Health → National Cancer Institute

Same awarding agency

NAICS: 541714
New
Grant
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Solicitation # PAR-28-042
The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

2 days ago

DEADLINE

in about 3 years
View Details
NAICS: 923120
Grant
Notice of Change: Grants Administration Information added for NCI's Participation on PA-27-036, NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)
Solicitation # NOT-CA-26-019
This Notice of Change, identified by solicitation number NOT-CA-26-019, updates the NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) under PA-27-036. The primary purpose of this amendment is to incorporate specific Grants Administration Information regarding the National Cancer Institute's participation in the program. The update specifically modifies Section VII, Agency Contacts, to include the Office of Grants Administration for the National Cancer Institute as a financial and grants management contact. No other changes have been made to the original PA-27-036 guidelines. Interested parties can coordinate with the Center for Cancer Training or the Office of Grants Administration for further inquiries.
Administration of Public Health Programs

POSTED

15 days ago

DEADLINE

N/A
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
Blood and Organ Banks

POSTED

21 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Solicitation # PAR-28-014
The National Cancer Institute, under the National Institutes of Health, is soliciting applications for solicitation PAR-28-014 to investigate the causes and biological mechanisms of sporadic non-hereditary early-onset cancers in adults aged 18 to 49. The primary goal of this initiative is to understand the rising incidence of these cancers to improve prevention and control strategies. Research should specifically target environmental or lifestyle drivers across various demographics, the biological host responses involved, or the development of more effective methods for identifying high-risk individuals. This funding opportunity supports both standard research projects and exploratory or developmental studies through a grant award instrument, with clinical trials being optional. Interested parties must submit their applications by the deadline of October 12, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

22 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541714
Grant
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Solicitation # PAR-28-022
The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

22 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541715
Grant
Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-013
The National Cancer Institute, under the National Institutes of Health, is seeking meritorious proposals for the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative. This solicitation, identified as RFA-CA-28-013, aims to fund projects that critically and systematically evaluate scientific evidence regarding carcinogenic hazards to humans to better inform cancer research, control, and prevention efforts. Interested applicants must submit their proposals by the response deadline of February 10, 2027. This opportunity is categorized as an R01 grant, and it is explicitly noted that clinical trials are not allowed under this specific funding program.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

27 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Notice of Change in Application Due Date for RFA-CA-27-005 "Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
Solicitation # NOT-CA-26-020
This notice issued by the National Cancer Institute of the National Institutes of Health serves to amend the application timeline for the Glioblastoma Therapeutics Network clinical trial solicitation, RFA-CA-27-005. The primary modification is the addition of a second application due date on January 11, 2027, for new, renewal, resubmission, and revision applications. Under this new cycle, the scientific merit review is scheduled for June 2027, followed by an advisory council review in August 2027, with an earliest start date of December 2027. The expiration date for this specific window is January 12, 2027. All other terms and conditions of the original notice of funding opportunity remain unchanged.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
Solicitation # PAR-28-057
The National Cancer Institute is soliciting applications under solicitation PAR-28-057 to establish the Management and Data Coordination Unit as a key scientific component of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients, aligning with the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The selected unit will be responsible for providing critical infrastructure and collaborative support, including study design, protocol development, statistical analysis, and comprehensive data management. Additionally, the unit will oversee the coordination of biorepository building and provide the necessary organizational and logistics support to ensure the successful operation of the consortium. Applications must be submitted by the deadline of May 26, 2027.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in 7 months
View Details
NAICS: 541714
Grant
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Solicitation # PAR-28-056
The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 3 years
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS